← Leaderboards
Stanley C Bell
Onconova Therapeutics, Inc.
$1,455,158
Attributed
$1,455,158
Total exposure
6
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $825.8K · FY2005–07$1M$750K$500K$250K$0
'05
'06
'07
Funding mix
By agency
NIH$1,455,158 · 6
By mechanism
R44$745,713 · 1
R43$709,445 · 5
Top collaborators
No co-investigators on record.
Most similar at Onconova Therapeutics, Inc.
Same institution · by research overlap
- Manoj Maniar$496,041
Others in their field
Top investigators on “Drug Design /Synthesis /Production”
- Dennis L. Kasper · Harvard Medical School$26,605,444
- Myron Max Levine · University Of Maryland Baltimore$22,074,862
- George R Painter · Chimerix, Inc.$19,230,662
- Donald L Fine · Dynport Vaccine Company, Llc$9,996,228
- Dennis E. Hruby · Oregon State University$9,654,233
- William C Olson · Progenics Pharmaceuticals, Inc.$8,361,679
Research focus
Drug Design /Synthesis /ProductionNonsteroidal Antiinflammatory AgentLaboratory MouseTissue /Cell CultureProstaglandin Endoperoxide SynthaseCerebral Ischemia /HypoxiaApoptosisEnzyme InhibitorsAmino Acids, Peptides, And ProteinsAnticancer TreatmentAlzheimer'S DiseaseAntigen TargetingAntineoplastic AgentsAntineoplasticsAffectAntibody ConjugateBinding (Molecular Function)AntibodiesAlkaliesBiologicalBiological ModelsBiotherapeutic AgentBiotinBenchmarking
Grant awards (7)
Evaluation of novel cytotoxic compounds for immunoconjugates$155,103
R43 · FY2007 · CA · contact PI
Use of Novel Cox-2 Inhibitors in Neurological Disorders$274,211
R44 · FY2006 · NS · contact PI
Use of Novel Cox-2 Inhibitors in Neurological Disorders$471,502
R44 · FY2005 · NS
Novel Cyclooxygenase-2 Inhibitors: Epileptogenesis$218,796
R43 · FY2005 · HL
Novel Therapeutic Strategy for Gliomas$135,546
R43 · FY2005 · CA
Pre-clinical Developmemt of a Novel COX-2 Inhibitor$100,000
R43 · FY2003 · CA
Use of Novel Cox-2 Inhibitors in Neurological Disorders$100,000
R43 · FY2003 · NS